<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990860</url>
  </required_header>
  <id_info>
    <org_study_id>ISS-13967</org_study_id>
    <secondary_id>ISS-13967</secondary_id>
    <nct_id>NCT00990860</nct_id>
  </id_info>
  <brief_title>Study in Asia of the Combination of TACE With Sorafenib in HCC Patients</brief_title>
  <acronym>START</acronym>
  <official_title>START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TACE possibly plays a significant role in contributing to a subgroup of surviving residual&#xD;
      tumor tissue which is characterized by more aggressive biology. This explains the strong&#xD;
      scientific rationale for exploring the role of anti-angiogenic therapy such as sorafenib to&#xD;
      remedy and strengthen the therapeutic efficacy of TACE to combat liver cancers. Sorafenib&#xD;
      plays a prominent auxiliary role by further suppressing the tumor growth and prolonging the&#xD;
      time to recurrence and progression. Performing TACE under sorafenib administration may have&#xD;
      synergic effect on hepatic tumoral lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (such as adverse events and laboratory changes (haematology, clinical chemistry))</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of TACE cycles</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE (Transcatheter arterial chemoembolization)</intervention_name>
    <description>TACE (Transcatheter arterial chemoembolization)</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≧ 18&#xD;
&#xD;
          -  life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Histologically diagnosed HCC, OR clinically diagnosed HCC for patients with difficulty&#xD;
             in obtaining histological diagnosis. A clinically diagnosed HCC should fulfill ALL the&#xD;
             criteria below&#xD;
&#xD;
               -  Chronic hepatitis B or C and/or evidence of liver cirrhosis.&#xD;
&#xD;
               -  Presence of hepatic tumour(s) with image findings compatible with HCC, and no&#xD;
                  evidence of other gastrointestinal tumours&#xD;
&#xD;
               -  A persistent elevation of serum AFP &gt;= 400 ng/ml without any evidence of an&#xD;
                  existing α-fetoprotein-secreting germ cell tumour&#xD;
&#xD;
          -  Child-Pugh score ≦ 7&#xD;
&#xD;
          -  BCLC B&#xD;
&#xD;
          -  The patient must have a solitary hepatic tumour greater than 3 cm in diameter or&#xD;
             multifocal disease as evidenced by CT or MRI scanning.&#xD;
&#xD;
          -  The target lesion must not have been previously treated with local therapy&#xD;
&#xD;
          -  The patient must not be a candidate for surgical resection or ablation of the tumour.&#xD;
             Size of largest tumor ≦10cm in largest dimension&#xD;
&#xD;
          -  Patients who have received previous local therapy treatments (RFA, PEI, cryoablation,&#xD;
             surgery, resection) to non-target lesions are eligible&#xD;
&#xD;
          -  Local therapy must have been completed at least 4 weeks prior to baseline scan.&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Hb ≧ 9g/dL,&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1000/mm3&#xD;
&#xD;
          -  Platelet count ≧ 60x109/L&#xD;
&#xD;
          -  Adequate clotting function: INR &lt; 1.5&#xD;
&#xD;
          -  Hepatic: AST or ALT &lt; 5 X ULN&#xD;
&#xD;
          -  Renal: serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Bilirubin ≦ 3mg/dL&#xD;
&#xD;
          -  The patient must give written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor factors&#xD;
&#xD;
               -  Presence of extrahepatic metastasis&#xD;
&#xD;
               -  Predominantly infiltrative lesion&#xD;
&#xD;
               -  Diffuse tumor morphology with extensive lesions involving both lobes.&#xD;
&#xD;
          -  Vascular complications&#xD;
&#xD;
               -  Hepatic artery thrombosis, or&#xD;
&#xD;
               -  Partial or complete thrombosis of the main portal vein, or&#xD;
&#xD;
               -  Tumor invasion of portal branch of contralateral lobe, or&#xD;
&#xD;
               -  Hepatic vein tumor thrombus, or&#xD;
&#xD;
               -  Significant arterioportal shunt not amenable to shunt blockage&#xD;
&#xD;
          -  Liver function&#xD;
&#xD;
               -  Advanced liver disease: ascites, hepatic encephalopathy&#xD;
&#xD;
               -  Patients with clinically significant gastrointestinal bleeding within the 30 days&#xD;
                  prior to study entry.&#xD;
&#xD;
          -  Others&#xD;
&#xD;
               -  Pregnant or lactating women.&#xD;
&#xD;
               -  Active sepsis or bleeding.&#xD;
&#xD;
               -  Hypersensitivity to intravenous contrast agents.&#xD;
&#xD;
               -  The patient has received prior treatment for HCC target lesion.&#xD;
&#xD;
               -  History of cardiac disease&#xD;
&#xD;
                    -  Congestive heart failure &gt; NYHA class 2; active coronary artery disease&#xD;
&#xD;
                    -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta&#xD;
                       blockers or digoxin.&#xD;
&#xD;
               -  Hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic pressure&#xD;
                  &gt; 90 mmHg despite optimal medical management.&#xD;
&#xD;
               -  Therapeutic anticoagulation with coumarin, heparins, or heparinoids.&#xD;
&#xD;
               -  Serious non-healing wounds (including wounds healing by secondary intention),&#xD;
                  acute or non-healing ulcers, or bone fractures within 3 months.&#xD;
&#xD;
               -  Impairment of swallowing that would preclude administration of sorafenib.&#xD;
&#xD;
               -  The patient is, in the opinion of the investigator, unable and / or unwilling to&#xD;
                  comply with treatment and study instructions.&#xD;
&#xD;
               -  Previous or concurrent cancer that is distinct in primary site or histology from&#xD;
                  HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial&#xD;
                  bladder tumors (Ta, Tis &amp; T1). Any cancer curatively treated &gt; 3 years prior to&#xD;
                  entry is permitted&#xD;
&#xD;
               -  Any active clinically serious infections (&gt; grade 2 NCI-CTCAE ver 3.0)&#xD;
&#xD;
               -  HIV infection or AIDS-related illness or serious acute or chronic illness (based&#xD;
                  on medical history)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yee Chao</last_name>
    <role>Principal Investigator</role>
    <affiliation>VGH-TPE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>E-Da hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital- Kaochiung</name>
      <address>
        <city>Kaoshiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital- Taichung</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri- Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital- Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital- LinKou</name>
      <address>
        <city>TaoYuan Hsien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>January 3, 2011</last_update_submitted>
  <last_update_submitted_qc>January 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yee Chao</name_title>
    <organization>Taipei Veterans General Hospital,Taiwan</organization>
  </responsible_party>
  <keyword>Combination of TACE With Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

